Studying the Effects of Flumazenil on Recovery After Intravenous Remimazolam Anesthesia in Patients Over 65 Having Hip Surgery

What this Trial Is About

Researchers are evaluating the effects of flumazenil on recovery after total intravenous anesthesia with remimazolam in elderly patients undergoing hip joint surgery. Remimazolam is a medication known for its short half-life and reversibility with flumazenil, but routine use of flumazenil is not currently recommended due to potential side effects such as rebound sedation and cardiac events. This study aims to clarify the necessity and impact of routinely using flumazenil in this setting, especially considering factors that may delay recovery like advanced age and obesity. Participants receive remimazolam combined with remifentanil for anesthesia. At the end of the procedure, they are randomly assigned to receive either 0.3 mg of flumazenil or 3 mL of normal saline placebo. Anesthesia is induced with remimazolam at 6 mgkgh and maintained at 1-2 mgkgh alongside remifentanil. The study compares recovery times and side effects between these two groups. During the study, participants are monitored for up to two hours after anesthesia to measure eye-opening and extubation times. Researchers also assess flumazenil dosage, any re-sedation episodes, and side effects from the drug until discharge from the post-anesthetic care unit. This randomized, double-blind trial involves older adults and includes careful observation of recovery and safety outcomes related to flumazenil use after remimazolam anesthesia.

Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam